iTeos Therapeutics, Inc. (ITOS)
NASDAQ: ITOS · Real-Time Price · USD
8.97
+0.16 (1.82%)
Nov 4, 2024, 4:00 PM EST - Market closed
iTeos Therapeutics Employees
iTeos Therapeutics had 157 employees as of December 31, 2023. The number of employees increased by 32 or 25.60% compared to the previous year.
Employees
157
Change (1Y)
32
Growth (1Y)
25.60%
Revenue / Employee
$222,930
Profits / Employee
-$688,758
Market Cap
327.60M
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 157 | 32 | 25.60% |
Dec 31, 2022 | 125 | 31 | 32.98% |
Dec 31, 2021 | 94 | 32 | 51.61% |
Dec 31, 2020 | 62 | 19 | 44.19% |
Dec 31, 2019 | 43 | - | - |
Related Stocks
Company Name | Employees |
---|---|
Viemed Healthcare | 996 |
Spok Holdings | 384 |
Jin Medical International | 245 |
CVRx, Inc. | 200 |
COMPASS Pathways | 186 |
Nautilus Biotechnology | 167 |
Biomea Fusion | 103 |
Jasper Therapeutics | 45 |
ITOS News
- 7 weeks ago - iTeos Therapeutics, Upstart Holdings And Other Big Stocks Moving Lower In Monday's Pre-Market Session - Benzinga
- 7 weeks ago - iTeos Therapeutics: ESMO Data Showing Signs Of A Real Win For TIGIT - Seeking Alpha
- 7 weeks ago - iTeos Announces Clinically Meaningful Objective Response Rate Observed at Every Dose in Follow-up Interim Analysis of GALAXIES Lung-201 Study of Belrestotug + Dostarlimab in First-Line, PD-L1 High Non-Small Cell Lung Cancer Patients - GlobeNewsWire
- 2 months ago - iTeos to Participate in Upcoming Investor Conferences - GlobeNewsWire
- 2 months ago - iTeos Therapeutics Announces Late-Breaking Oral Presentation of Phase 2 GALAXIES Lung-201 Interim Data at the European Society for Medical Oncology Congress 2024 - GlobeNewsWire
- 3 months ago - iTeos Therapeutics Announces Appointment of David Feltquate as Chief Medical Officer - GlobeNewsWire
- 4 months ago - iTeos Therapeutics: Rippling Waves Of TIGIT Pessimism - Seeking Alpha
- 4 months ago - iTeos Announces First Patient Dosed in GALAXIES Lung-301 Phase 3 Study, Earning $35 Million in Milestones from GSK - GlobeNewsWire